ストックスクリーナーアプリを入手
107.05
0.14%
0.145
プレマーケット:
106.10
-0.945
-0.88%
前日終値:
$106.90
開ける：
$106.38
24時間の取引高:
311.07K
Relative Volume:
0.54
時価総額：
$8.31B
収益：
-
当期純損益:
$-224.29M
株価収益率:
-27.45
EPS:
-3.9
ネットキャッシュフロー:
$-185.06M
1週間 パフォーマンス:
-1.85%
1か月 パフォーマンス:
+17.61%
6か月 パフォーマンス:
+39.35%
1年 パフォーマンス:
+13.61%
1日の値動き範囲:
$104.95
$108.04
1週間の範囲:
$103.51
$109.45
52週間の値動き範囲:
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
NUVL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
107.05 | 8.30B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-12 | 開始されました | Canaccord Genuity | Buy |
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-10-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-09-03 | 開始されました | Raymond James | Outperform |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-03-14 | アップグレード | UBS | Neutral → Buy |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-08-29 | 開始されました | Barclays | Overweight |
| 2024-04-17 | 開始されました | Jefferies | Buy |
| 2024-04-01 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 再開されました | Guggenheim | Buy |
| 2024-02-23 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-27 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-24 | 開始されました | Guggenheim | Buy |
| 2023-01-18 | 開始されました | Wedbush | Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
すべてを表示
Nuvalent Inc (NUVL) 最新ニュース
Layoff Watch: Is Nuvalent Inc stock trading at a premium valuationEarnings Growth Summary & Free Expert Verified Stock Movement Alerts - BỘ NỘI VỤ
NUVL: Late-stage oncology assets show strong efficacy and safety, with first approvals targeted for 2026 - TradingView
Will Nuvalent Inc. stock attract more institutional investorsMarket Sentiment Summary & Long-Term Safe Investment Ideas - Newser
Nuvalent Insider Sold Shares Worth $434,319, According to a Recent SEC Filing - marketscreener.com
(NUVL) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Returns Recap: Is Nuvalent Inc. stock trading near support levelsJuly 2025 Volume & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - Eastern Progress
Does Nuvalent’s Recent Trial Success Justify the Stock’s 36% 2025 Rally? - Yahoo Finance
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Nuvalent to Participate in the Piper Sandler 37th Annual Healthc - GuruFocus
Nuvalent: Deerfield funds sell $70.8m in NUVL stock By Investing.com - Investing.com South Africa
Nuvalent (NUVL) Receives a New Rating from Truist Financial - The Globe and Mail
Nuvalent’s Cash Cushion Keeps Investors On Board Through Setbacks - Finimize
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders - Finviz
Nuvalent: Deerfield funds sell $70.8m in NUVL stock - Investing.com
Nuvalent closes $500 million public offering of common stock By Investing.com - Investing.com South Africa
Nuvalent Announces Closing of Public Offering of Common Stock an - GuruFocus
Nuvalent Closes Public Offering of Common Shares - marketscreener.com
Nuvalent closes $500 million public offering of common stock - Investing.com
Nuvalent (NASDAQ: NUVL) closes $500M stock offering; 4,950,496 shares sold in public deal - Stock Titan
Nuvalent announces public offering of common stock - MSN
FDA accepts NDA for Nuvalent's zidesamtinib for non-small cell lung cancer - MSN
J.P. Morgan Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Four companies raise nearly $950M in follow-ons: Public Equity Report - BioCentury
Nuvalent Announces $500M Stock Offering Pricing - The Globe and Mail
Biotech Stock Gets Booted in Latest Fund Update - AOL.com
Will Nuvalent Inc. stock keep outperforming rivalsJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Why analysts upgrade Nuvalent Inc. stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Sidley Represents Nuvalent in Pricing of US$500 Million Public Offering - Legal Desire Media and Insights
Jefferies raises Nuvalent stock price target to $164 on promising cancer drug data - Investing.com Nigeria
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - The Malaysian Reserve
Can Nuvalent Inc. stock surprise with earnings upsideWeekly Trade Report & Safe Capital Growth Plans - newser.com
Will Nuvalent Inc. stock reach Wall Street targetsPortfolio Return Report & Accurate Buy Signal Notifications - newser.com
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment By Investing.com - Investing.com Nigeria
Nuvalent Insider Sold Shares Worth $2,065,030, According to a Recent SEC Filing - MarketScreener
Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer - marketscreener.com
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment - Investing.com
Nuvalent Executives Sell Over $4.6 Million in Stock - TradingView
Nuvalent Announces FDA Acceptance of New Drug Application for Zi - GuruFocus
CFO Balcom Sells 20,729 ($2.1M) Of Nuvalent Inc [NUVL] - TradingView
Nuvalent Inc (NUVL) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):